标题
Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability
作者
关键词
-
出版物
NEUROUROLOGY AND URODYNAMICS
Volume 33, Issue 1, Pages 17-30
出版商
Wiley
发表日期
2013-10-14
DOI
10.1002/nau.22505
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Role of Cytochrome P450 Isoenzymes 3A and 2D6 in the In Vivo Metabolism of Mirabegron, a β3-Adrenoceptor Agonist
- (2013) Jennifer Lee et al. CLINICAL DRUG INVESTIGATION
- 401 The incidence of antimuscarinic-associated side effects in overactive bladder (OAB) patients treated with mirabegron: Results of a pooled analysis of 3 randomised phase 3 trials
- (2013) V. Nitti et al. EUROPEAN UROLOGY SUPPLEMENTS
- Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies
- (2013) V. W. Nitti et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- A phase II dose-ranging study of mirabegron in patients with overactive bladder
- (2013) Christopher R. Chapple et al. INTERNATIONAL UROGYNECOLOGY JOURNAL
- Randomized, Double-Masked, Placebo-Controlled Study to Assess the Ocular Safety of Mirabegron in Healthy Volunteers
- (2013) Gary D. Novack et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- 1958 COMBINATION TREATMENT WITH MIRABEGRON AND SOLIFENACIN IN PATIENTS WITH OVERACTIVE BLADDER (OAB) - EFFICACY RESULTS FROM A PHASE 2 STUDY (SYMPHONY)
- (2013) Paul Abrams et al. JOURNAL OF UROLOGY
- Urodynamics and Safety of the β3-Adrenoceptor Agonist Mirabegron in Males with Lower Urinary Tract Symptoms and Bladder Outlet Obstruction
- (2013) Victor W. Nitti et al. JOURNAL OF UROLOGY
- Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome
- (2013) Yasuhiko Igawa et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience
- (2012) Adrian Wagg et al. BJU INTERNATIONAL
- Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study
- (2012) M Malik et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the β3-Adrenoceptor Agonist Solabegron for Overactive Bladder
- (2012) Eliot H. Ohlstein et al. EUROPEAN UROLOGY
- Mirabegron as a New Class of Oral Drug for Overactive Bladder Syndrome: Many Positive Perspectives, Some Concerns
- (2012) Giacomo Novara et al. EUROPEAN UROLOGY
- Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder
- (2012) Christopher R. Chapple et al. EUROPEAN UROLOGY
- Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial
- (2012) Vik Khullar et al. EUROPEAN UROLOGY
- 684 Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder (OAB): Post-hoc analysis of a prospective, randomised European-Australian phase III trial
- (2012) V. Khullar et al. EUROPEAN UROLOGY SUPPLEMENTS
- OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial
- (2012) Victor W. Nitti et al. JOURNAL OF UROLOGY
- Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder
- (2012) Victor W. Nitti et al. JOURNAL OF UROLOGY
- Bladder selectivity of the novel β3-agonist ritobegron (KUC-7483) explored by in vitro and in vivo studies in the rat
- (2012) Itaru Maruyama et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- In vitroinhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist
- (2012) Shin Takusagawa et al. XENOBIOTICA
- Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist
- (2012) Shin Takusagawa et al. XENOBIOTICA
- Content validity and test-retest reliability of patient perception of intensity of urgency scale (PPIUS) for overactive bladder
- (2012) Sherilyn M Notte et al. BMC Urology
- Pharmacological Effect of TRK-380, a Novel Selective Human β3-Adrenoceptor Agonist, on Mammalian Detrusor Strips
- (2011) Sayoko Kanie et al. UROLOGY
- Patient-reported reasons for discontinuing overactive bladder medication
- (2009) Joshua S. Benner et al. BJU INTERNATIONAL
- The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis
- (2008) Christopher R. Chapple et al. EUROPEAN UROLOGY
- Catecholamines Relax Detrusor through 2-Adrenoceptors in Mouse and 3-Adrenoceptors in Man
- (2008) M. Wuest et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Expression and functional role of β-adrenoceptors in the human urinary bladder urothelium
- (2008) Atsushi Otsuka et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started